Biomatter Raises $18 Million to Speed Enzyme Design

The Lithuanian company's Series A round, led by Astanor, will fund a planned enzyme design and testing facility in Vilnius.

Updated on Nov. 12, 2026 in Biotech

Bold flat-color vector editorial illustration showing a row of bioreactor vessels and tubes on a teal bench, suggesting computational enzyme engineering.
Biomatter raised $18 million in a Series A round led by Astanor to expand its computational enzyme design work, which the company says can shorten development from months to weeks. AI Illustration. Upload story photo >

Biomatter, a company specialising in custom enzyme design, raised $18 million in an oversubscribed Series A funding round led by Astanor. UVC Partners, Inventure and Metaplanet participated as existing investors.

Why it matters

Conventional enzyme development can take months or even years, particularly when naturally occurring enzymes are unsuitable for specific applications. Biomatter says its computational approach currently shortens that process to weeks.

Biomatter combines computational models with laboratory testing and draws on a proprietary dataset of experimentally characterised enzymes that expands with each programme. Independent verification of its weeks-long design timeline has not been reported.

The players

Biomatter

A Lithuanian company specialising in custom enzyme design that combines computational models with laboratory testing.

Astanor

An investment firm that led Biomatter's oversubscribed Series A funding round.

The details

Biomatter develops computational technology to design enzymes for specific chemical reactions, and has built custom enzymes for AstraZeneca, BASF, Sanofi and Tereos. It also developed an enzyme with Thermo Fisher Scientific to improve stability for molecular biology and mRNA research, and designed a methylase for mRNA vaccine manufacturing that operates without S-adenosylmethionine (SAM).

Timeline

  1. November 12, 2026: Biomatter announces its $18 million Series A funding round.

  2. 2027: Scheduled opening of the planned 2,000-square-metre enzyme design and testing facility in Vilnius.

The Tech Race

Biomatter's SAM-free methylase for mRNA vaccine manufacturing places it among firms competing to replace costly, conventional enzyme processes in biologics production. Its speed claim positions computational enzyme design against slower traditional development methods used across the pharmaceutical industry.

Faster enzyme design could shorten development timelines for the medicines, vaccines and industrial products that rely on custom enzymes. Consumers are unlikely to see direct effects until the enzymes reach commercial products.

The takeaway

Computational enzyme design could make custom biological tools faster to develop, which may matter as mRNA vaccine and pharmaceutical manufacturing scale up. Readers tracking biotech should watch whether the claimed weeks-long timelines hold up outside the company's own reporting.

What happens next

The Vilnius enzyme design and testing facility is scheduled to open in 2027, and Biomatter plans to expand its commercial team in the United States.

Further reading

Explore more biotech developments shaping enzyme design and drug manufacturing.